Lovastatin effects on bone mineral density in postmenopausal women with type 2 diabetes mellitus

Acta Diabetologica

Volumn 44, Issue 2, 2007, Pages 76-82

  Safaei, H ^a   Janghorbani, M ^b   Aminorroaya, A ^a   Amini, M ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bone mineral density; Diabetes mellitus; Lovastatin; Postmenopause; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN;

ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; FEMUR NECK; HIP; HUMAN; LUMBAR SPINAL CORD; LUMBAR SPINE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTMENOPAUSE; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME;

AGED; BONE DENSITY; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DENSITOMETRY, X-RAY; DIABETES MELLITUS, TYPE 2; FEMALE; FEMUR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; LUMBAR VERTEBRAE; MIDDLE AGED; POSTMENOPAUSE;

EID: 34249720461     PISSN: 09405429     EISSN: 14325233     Source Type: Journal    
DOI: 10.1007/s00592-007-0246-6     Document Type: Article

References (35)

1. Anon (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646-650
2. Cummings SR, Nevitt MC, Browner WS, Stone K, Fox KM, Ensrud KE, Cauley J, Black D, Vogt TM (1995) Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group. N Engl J Med 332:767-773
3. Ettinger B, Pressman A, Sklarin P, Bauer DC, Cauley JA, Cummings SR (1998) Associations between low levels of serum estradiol, bone density, and fractures among elderly women: the study of osteoporotic fractures. J Clin Endocrinol Metab 83:2239-2243
4. Slemenda C, Longcope C, Peacock M, Hui S, Johnston CC (1996) Sex steroids, bone mass, and bone loss. A prospective study of pre-, peri-, and postmenopausal women. J Clin Invest 97:14-21
5. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB; Women's Health Initiative Investigators (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290:1729-1738
6. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G (2002) Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516
7. Riggs BL, Hartmann LC (2003) Selective estrogen-receptor modulators - mechanisms of action and application to clinical practice. N Engl J Med 348:618-629
8. Liao JK (2002) Isoprenoids as mediators of the biological effects of statins. J Clin Invest 110:285-288
9. Mundy G, Garrett R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutierrez G (1999) Stimulation of bone formation in vitro and in rodents by statins. Science 286:1946-1949
10. Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA (2004) Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials. Arch Intern Med 164:146-152
11. Braatvedt GD, Bagg W, Gamble G, Davidson J, Reid IR (2004) The effect of atorvastatin on markers of bone turnover in patients with type 2 diabetes. Bone 35:766-770
12. Chung YS, Lee MD, Lee SK, Kim HM, Fitzpatrick LA (2000) HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 85:1137-1142
13. Nakashima A, Nakashima R, Ito T, Masaki T, Yorioka N (2004) HMG-CoA reductase inhibitors prevent bone loss in patients with Type 2 diabetes mellitus. Diabet Med 2:1020-1024
14. Pedersen TR, Kjekshus J (2000) Statin drugs and the risk of fracture. 4S Study Group. JAMA 284:1921-1922
15. Reid IR, Hague W, Emberson J, Baker J, Tonkin A, Hunt D, MacMahon S, Sharpe N (2001) Effect of pravastatin on frequency of fracture in the LIPID study: secondary analysis of a randomised controlled trial. Long-term Intervention with Pravastatin in Ischaemic Disease. Lancet 357:509-512
16. Wang PS, Solomon DH, Mogun H, Avorn J (2000) HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 283:3211-3216
17. Whitfield JF (2001) Statins: new drugs for treating osteoporosis? Expert Opin Investig Drugs 10:409-415
18. Wakasugi M, Wakao R, Tawata M, Gan N, Koizumi K, Onaya T (1993) Bone mineral density measured by dual energy X-ray absorptiometry in patients with non-insulin-dependent diabetes mellitus. Bone 14:29-33
19. van Daele PL, Stolk RP, Burger H, Algra D, Grobbee DE, Hofman A, Birkenhager JC, Pols HA (1995) Bone density in non-insulin-dependent diabetes mellitus. The Rotterdam Study. Ann Intern Med 122:409-414
20. Schwartz AV, Sellmeyer DE, Ensrud KE, Cauley JA, Tabor HK, Schreiner PJ, Jamal SA, Black DM, Cummings SR (2001) Older women with diabetes have an increased risk of fracture: a prospective study. J Clin Endocrinol Metab 86:32-38
21. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ; Blue Mountains Eye Study (2001) Diabetes and risk of fracture: The Blue Mountains Eye Study. Diabetes Care 24:1198-1203
22. Gregorio F, Cristallini S, Santeusanio F, Filipponi P, Fumelli P (1994) Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract 23:43-54
23. Sosa M, Dominguez M, Navarro MC, Segarra MC, Hernandez D, de Pablos P, Betancor P (1996) Bone mineral metabolism is normal in non-insulin-dependent diabetes mellitus. J Diabetes Complications 10:201-205
24. Isaia GC, Ardissone P, Di Stefano M, Ferrari D, Martina V, Porta M, Tagliabue M, Molinatti GM (1999) Bone metabolism in type 2 diabetes mellitus. Acta Diabetol 36:35-38
25. Amayo AA, Kirera S (2004) Comparison of calculated and direct low density lipoprotein cholesterol determinations in a routine laboratory. East Afr Med J 81:154-158
26. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585-590
27. Chan KA, Andrade SE, Boles M, Buist DS, Chase GA, Donahue JG, Goodman MJ, Gurwitz JH, LaCroix AZ, Platt R (2000) Inhibitors of hydroxymethylglutaryl- coenzyme A reductase and risk of fracture among older women. Lancet 355:2185-2188
28. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H (2000) HMG-CoA reductase inhibitors and the risk of fractures. JAMA 283:3205-3210
29. Pasco JA, Kotowicz MA, Henry MJ, Sanders KM, Nicholson GC (2002) Statin use, bone mineral density, and fracture risk: Geelong Osteoporosis Study. Arch Intern Med 162:537-540
30. Sirola J, Sirola J, Honkanen R, Kroger H, Jurvelin JS, Maenpaa P, Saarikoski S (2002) Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int 13:537-541
31. van Staa TP, Wegman S, de Vries F, Leufkens B, Cooper C (2001) Use of statins and risk of fractures. JAMA 285:1850-1855
32. Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L (2004) Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women. J Bone Miner Res 19:737-744
33. Wada Y, Nakamura Y, Koshiyama H (2000) Lack of positive correlation between statin use and bone mineral density in Japanese subjects with type 2 diabetes. Arch Intern Med 160:2865
34. Grasser WA, Baumann AP, Petras SF, Harwood HJ Jr, Devalaraja R, Renkiewicz R, Baragi V, Thompson DD, Paraklar VM (2003) Regulation of osteoclast differentiation by statins. J Musculoskeletal Neuronal Interact 3:53-62
35. Inaba M, Nishizawa Y, Mita K, Kumeda Y, Emoto M, Kawagishi T, Ishimura E, Nakatsuka K, Shioi A, Morii H (1999) Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporos Int 9:525-531